Overview
Integra LifeSciences Holdings Corporation, based in the United States, is a prominent player in the medical technology industry. The company specializes in developing, manufacturing, and marketing surgical instruments, devices, and implants primarily utilized in neurosurgery, reconstructive surgery, and general surgery. A key focus for Integra LifeSciences is its work in tissue regeneration, where it develops products that promote the regrowth of soft tissues and bones. Its extensive product portfolio includes the likes of DuraGen, a dural graft matrix widely used in neurosurgery, and innovative orthobiologic products that assist in bone healing. Integra LifeSciences’s strategic initiatives aim at expanding its global footprint through acquisitions and increasing penetration in existing markets, thereby enhancing its impact on healthcare solutions worldwide.
Basic Stats
The share price of Integra LifeSciences Holdings Corporation as of September 5, 2025 is $16.00 / share. This is an increase of 5.75% from the prior week. The market cap (or net worth) of Integra LifeSciences Holdings Corporation as of September 5, 2025 is $2,493.15 MM.
The Factor Analysis chart (below right) shows a view of Integra LifeSciences Holdings Corporation from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 2,493.15 MM |
| EV | 4,117.51 MM |
| Shares Out. | 77.92 MM |
| Earnings Date | |
| EPS (TTM) | -6.42 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.47 |
| Short Shares Avail. | 1.00 MM |
| Short Interest | 7.29 MM |
| Short Float | 12.31 % |
| Days to Cover | 6.38 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -16.62 % |
| Volatility (1 yr) | 0.60 |
| Beta | 0.75 |
| Sharpe Ratio (1 yr) | -0.34 |
| Sortino Ratio (1 yr) | -0.58 |
| PE Ratio | -4.98 |
| Price/Book | 2.40 |
| Price/TBV | -3.26 |
| Book/Market | 0.42 |
| EBIT/EV | -0.14 |
| EBIT(3yr avg)/EV | -0.03 |
| ROA | -0.12 |
| ROE | -0.33 |
| ROIC | -0.16 |
| CROIC | 0.00 |
| OCROIC | 0.02 |
| Implied Volatility | 72.88 % |
| Put/Call OI Ratio | 0.12 |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Integra LifeSciences Holdings Corporation is $16.76. The forecasts range from a low of $10.10 to a high of $31.50. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Integra LifeSciences Holdings Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-06 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-12-20 | Truist Securities | Hold | Maintains | |
| 2022-12-12 | Citigroup | Neutral | Maintains | |
| 2022-10-27 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-10-27 | JMP Securities | Market Outperform | Maintains | |
| 2022-10-17 | Truist Securities | Hold | Maintains | |
| 2022-10-12 | Jefferies | Hold | Initiate | |
| 2022-10-11 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-08-25 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-07-25 | Morgan Stanley | Equal-Weight | Initiate | |
| 2022-07-20 | Truist Securities | Hold | Maintains | |
| 2022-05-17 | Citigroup | Neutral | Maintains | |
| 2022-01-18 | B of A Securities | Underperform | Maintains | |
| 2021-12-17 | JP Morgan | Underweight | Neutral | Upgrade |
| 2021-11-03 | Credit Suisse | Outperform | Maintains | |
| 2021-09-15 | BTIG | Buy | Neutral | Downgrade |
| 2021-02-19 | Credit Suisse | Outperform | Maintains | |
| 2021-01-27 | JMP Securities | Market Outperform | Maintains | |
| 2021-01-07 | Credit Suisse | Outperform | Maintains | |
| 2020-10-29 | Piper Sandler | Neutral | Maintains | |
| 2020-10-08 | JP Morgan | Neutral | Underweight | Downgrade |
| 2020-08-12 | Truist Securities | Buy | Maintains | |
| 2020-08-11 | UBS | Neutral | Maintains | |
| 2020-08-11 | Credit Suisse | Outperform | Maintains | |
| 2020-05-08 | UBS | Neutral | Maintains | |
| 2020-05-08 | JMP Securities | Market Outperform | Maintains | |
| 2020-05-08 | Credit Suisse | Outperform | Maintains | |
| 2020-04-06 | Wells Fargo | Equal-Weight | Maintains | |
| 2020-04-03 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2020-03-06 | Credit Suisse | Outperform | Maintains | |
| 2020-02-20 | UBS | Neutral | Maintains | |
| 2020-01-07 | Piper Sandler | Overweight | Neutral | Downgrade |
| 2019-12-18 | UBS | Neutral | Maintains | |
| 2019-10-08 | Wells Fargo | Market Perform | Maintains | |
| 2019-01-03 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2018-12-18 | Credit Suisse | Outperform | Initiate | |
| 2018-12-12 | Credit Suisse | Outperform | Initiate | |
| 2018-11-28 | UBS | Neutral | Initiate | |
| 2018-11-02 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2018-11-02 | Citigroup | Neutral | Neutral | Maintains |
| 2018-11-01 | Wells Fargo | Market Perform | Market Perform | Maintains |
| 2018-11-01 | Cantor Fitzgerald | Neutral | Neutral | Maintains |
| 2018-10-11 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-08-07 | Bank of America | Neutral | Underperform | Downgrade |
| 2018-07-26 | BTIG Research | Neutral | Buy | Upgrade |
| 2018-07-02 | Citigroup | Buy | Neutral | Downgrade |
| 2018-05-22 | JP Morgan | Neutral | Neutral | Maintains |
| 2018-04-26 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-04-26 | JP Morgan | Neutral | Neutral | Maintains |
| 2018-04-11 | JP Morgan | Neutral | Neutral | Maintains |
| 2018-04-05 | BTIG Research | Neutral | Initiate | |
| 2018-02-28 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2018-01-02 | Raymond James | Outperform | Market Perform | Downgrade |
| 2018-01-02 | Bank of America | Buy | Neutral | Downgrade |
| 2017-10-30 | Wells Fargo | Outperform | Market Perform | Downgrade |
| 2017-10-27 | JP Morgan | Overweight | Neutral | Downgrade |
| 2017-07-27 | Raymond James | Outperform | Maintains | |
| 2017-07-10 | Morgan Stanley | Neutral | Maintains | |
| 2017-06-30 | Cantor Fitzgerald | Overweight | Initiate | |
| 2017-01-06 | JMP Securities | Market Perform | Market Outperform | Upgrade |
| 2016-12-12 | UBS | Buy | Initiate | |
| 2016-10-28 | Lake Street | Hold | Buy | Upgrade |
| 2016-09-23 | Argus | Buy | Maintains | |
| 2016-07-29 | Jefferies | Buy | Maintains | |
| 2016-07-29 | Barclays | Equal-Weight | Maintains | |
| 2016-07-13 | JP Morgan | Overweight | Initiate | |
| 2016-06-02 | Barclays | Equal-Weight | Maintains | |
| 2016-04-28 | Lake Street | Hold | Maintains | |
| 2015-11-12 | Citigroup | Buy | Initiate | |
| 2015-09-21 | Bank of America | Neutral | Buy | Upgrade |
| 2015-07-31 | JP Morgan | Neutral | Overweight | Upgrade |
| 2015-07-29 | Raymond James | Market Perform | Outperform | Upgrade |
| 2015-05-29 | Barclays | Equal-Weight | Maintains | |
| 2015-05-01 | Wells Fargo | Market Perform | Outperform | Upgrade |
| 2015-05-01 | Barclays | Equal-Weight | Maintains | |
| 2015-03-10 | PiperJaffray | Overweight | Initiate | |
| 2015-02-27 | Jefferies | Buy | Maintains | |
| 2014-08-06 | Oppenheimer | Outperform | Maintains | |
| 2014-05-02 | Oppenheimer | Outperform | Maintains | |
| 2014-04-23 | Lake Street | Buy | Initiate | |
| 2014-01-08 | Bank of America | Underperform | Neutral | Upgrade |
| 2013-11-11 | Morgan Stanley | Underweight | Neutral | Upgrade |
| 2013-10-23 | Morgan Stanley | Equal-Weight | Underweight | Downgrade |
| 2013-10-04 | Barclays | Equal-Weight | Initiate | |
| 2013-08-15 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2013-08-02 | Oppenheimer | Outperform | Maintains | |
| 2013-06-04 | Wells Fargo | Market Perform | Initiate | |
| 2013-04-11 | PiperJaffray | Neutral | Maintains | |
| 2013-02-28 | JP Morgan | Neutral | Maintains | |
| 2013-02-22 | PiperJaffray | Neutral | Maintains | |
| 2013-02-22 | Jefferies | Buy | Maintains | |
| 2013-01-11 | Janney Capital | Buy | Initiate | |
| 2012-12-18 | Bank of America | Neutral | Underperform | Downgrade |
| 2012-11-16 | SunTrust Robinson Humphrey | Neutral | Initiate | |
| 2012-09-10 | Oppenheimer | Outperform | Maintains | |
| 2012-07-30 | PiperJaffray | Neutral | Maintains | |
| 2012-07-27 | Jefferies | Buy | Maintains | |
| 2012-06-27 | Bank of America | Neutral | Maintains | |
| 2012-04-27 | JP Morgan | Neutral | Maintains | |
| 2012-04-27 | Jefferies | Buy | Maintains | |
| 2012-04-24 | Bank oferica | Neutral | Maintains | |
| 2012-02-24 | PiperJaffray | Neutral | Maintains | |
| 2012-02-22 | JP Morgan | Neutral | Maintains | |
| 2023-02-23 | Citigroup | Neutral | Maintains | |
| 2023-04-27 | JMP Securities | Outperform | Maintains | |
| 2023-04-17 | Truist Securities | Hold | Maintains | |
| 2023-05-24 | JP Morgan | Neutral | Underweight | Downgrade |
| 2023-05-30 | Truist Securities | Hold | Hold | Reiterate |
| 2023-05-23 | Citigroup | Neutral | Sell | Downgrade |
| 2023-05-18 | Truist Securities | Hold | Hold | Maintains |
| 2023-05-31 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-05-26 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-06-08 | Argus Research | Buy | Hold | Downgrade |
| 2023-07-19 | Truist Securities | Hold | Hold | Maintains |
| 2023-07-12 | Jefferies | Hold | Buy | Upgrade |
| 2023-07-28 | JMP Securities | Outperform | Outperform | Maintains |
| 2023-08-24 | Morgan Stanley | Equal-Weight | Underweight | Downgrade |
| 2023-12-05 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| 2024-02-29 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2023-12-22 | Truist Securities | Hold | Hold | Maintains |
| 2023-11-14 | CL King | Buy | Initiate | |
| 2023-12-14 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-12-14 | Truist Securities | Hold | Hold | Maintains |
| 2023-10-26 | Truist Securities | Hold | Hold | Maintains |
| 2023-10-26 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2024-04-03 | Citigroup | Sell | Neutral | Upgrade |
| 2024-05-07 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-05-07 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2024-05-07 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2024-05-07 | Truist Securities | Hold | Hold | Maintains |
| 2024-05-07 | B of A Securities | Underperform | Underperform | Maintains |
| 2024-05-22 | Citigroup | Neutral | Neutral | Maintains |
| 2024-03-01 | Truist Securities | Hold | Hold | Maintains |
| 2024-07-15 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2024-07-10 | Citigroup | Neutral | Neutral | Maintains |
| 2024-07-16 | Truist Securities | Hold | Hold | Maintains |
| 2024-11-05 | Citigroup | Sell | Sell | Maintains |
| 2025-05-09 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-08-28 | BTIG | Sell | Sell | Maintains |
| 2024-07-30 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-07-30 | Truist Securities | Hold | Hold | Maintains |
| 2024-10-07 | BTIG | Sell | Neutral | Upgrade |
| 2024-10-07 | B of A Securities | Underperform | Underperform | Maintains |
| 2024-08-22 | Citigroup | Sell | Sell | Maintains |
| 2025-04-11 | Truist Securities | Hold | Hold | Maintains |
| 2024-07-30 | Citigroup | Neutral | Sell | Downgrade |
| 2024-07-30 | BTIG | Neutral | Sell | Downgrade |
| 2025-03-31 | Argus Research | Hold | Buy | Upgrade |
| 2024-10-14 | Truist Securities | Hold | Hold | Maintains |
| 2024-10-01 | Citigroup | Sell | Sell | Maintains |
| 2025-02-26 | Citizens Capital Markets | Market Outperform | Market Outperform | Reiterate |
| 2025-05-06 | JP Morgan | Underweight | Underweight | Maintains |
| 2025-05-06 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
